SomnoMed at World Sleep 2022

About SomnoMed®

Founded in 2004, SomnoMed® is an Australian Stock Exchange listed medical device company operating in 28 countries.

With headquarters in Sydney, Australia and offices in Europe and the United States, SomnoMed® focuses on developing and manufacturing clinically proven medical devices for the treatment of Obstructive Sleep Apnea (OSA). More than 625,000 patients around the world with mild and moderate OSA have been successfully treated with our oral appliances.

For US customers: This device is pending FDA clearance and is not available for sale in the United States.

For customers outside of the US: This device is under review by regulatory authorities in your country and will not be sold or used until approval is received.